Risperidone Boosts ADHD Stimulant Medication Effects
by
Nicolas I.Posted
Thu 22 Jan 2009 6:54pm1 Comment
ADHD Medications
Risperidone Boosts Stimulants' Effectiveness for ADHD and Conduct Disorders
We often search the fine print for ADHD medication labels to see... conduct disorders and evaluate the relative safety of these medication combos.
The drug Risperidone (also referred to as Risperdal or Rispen ), is a relatively new antipsychotic
Read on »
From Risperidone to Ritalin: Lies. Lies. Lies. And Children Are in Danger.
by
Kim S.Posted
Fri 27 Mar 2009 9:21am
By Kim Stagliano Two articles in one week should shake parents of kids with autism, Asperger's and ADHD who are on powerful meds to their core. In the first, we learn that Harvard Psychiatrist Dr. Joseph Biederman promised postitive results...
Read on »
Risperidone-Induced Weight Gain in Referred Children with Autism Spectrum Disorders
by
Kev LeitchPosted
Thu 30 Dec 2010 10:08amRisperidone, also known as Risperdal, is the one drug FDA approved for treatment of irritability and behavior issues some autistics have. According to Vincent Iannelli, M.D., at about.com, these include:
aggression
deliberate self-injury
temper tantrums
quickly changing moods
Risperidone is serious medicine
Read on »
From Risperidone to Ritalin: Lies. Lies. Lies. And Children Are in Danger.
by
Kim S.Posted
Fri 27 Mar 2009 12:00am
. In the first, we learn that Harvard Psychiatrist Dr. Joseph Biederman promised postitive results to Johnson & Johnson in risperidone testing. (HERE). From the NYT: An influential Harvard... executives. One slide referred to a proposed trial in preschool children of risperidone, an antipsychotic drug made by the drug company. The trial, the slide stated, “will support
Read on »
RISPERDAL CONSTA (risperidone) l ...
by
Dr. Rubens D.Posted
Wed 20 May 2009 10:18am
RISPERDAL CONSTA (risperidone) long-acting treatment delayed the time to relapse in patients with Bipolar I Disorder
SAN FRANCISCO, 20 may 2009 – New data demonstrate that maintenance therapy with RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment (RLAT) significantly delayed the time to relapse compared to placebo in patients with Bipolar I Disorder
Read on »
Treating Neuropsychiatric Symptoms in Dementia With Lewy Bodies: A Randomized Co
by
Neurodoc ..Posted
Tue 20 Jul 2010 8:30am
conditions the tolerability and efficacy of citalopram and risperidone in the treatment of behavioral and psychotic symptoms in patients with DLB and Alzheimer disease (AD). Thirty-one participants with DLB and 66 with AD hospitalized for behavioral disturbance were treated under randomized, double-blind conditions with citalopram or risperidone for up
Read on »
Meds plus behavior management for Autism
by
JohnLPosted
Sun 01 Nov 2009 12:00am
Michael Aman and co-authors (and there are at least 25 of them) reported that a combination of medication and parent training in behavior management was more effective than medication alone in reducing behavior problems. They assigned families randomly assigned to receive either risperidone as well as parent management training or risperidoneRead on »
CATIE-AD study
by
Neurodoc ..Posted
Fri 17 Oct 2008 9:12pm
MMSE 15 enrolled at 42 sites. Subjects were randomized to placebo, 5.5 mg/d olanzepine, 1 mg/day risperidone, or 56.5 mg/day of quetiapine. Endpoint was the time until... risperidone or olanzepine, and sedation with olanzepine and quetiapine (more than risperidone). Cognitive disturbances were higher in patients on olanzepine (7%) and increased
Read on »
Sharyl Attkisson Explores Off Label Use of Risperdal in Children
by
Kim S.Posted
Wed 27 May 2009 12:00am
Biederman promised postitive results to Johnson & Johnson in risperidone testing. The psychiatrist, Dr. Joseph Biederman, outlined plans to test Johnson & Johnson’s drugs in presentations to company executives. One slide referred to a proposed trial in preschool children of risperidone, an antipsychotic drug made by the drug company. The trial, the slide
Read on »
Risperdal Consta Approved for Bipolar Disorder
by
Ulysee W.Posted
Mon 18 May 2009 10:36pm
J&J’s Janssen has received approval from the FDA for the long-acting version of Risperdal Consta (risperidone) for the treatment of bipolar I disorder. Risperdal Consta was approved for schizophrenia in 2003.
Also benefitting from the announcement is Boston biotech Alkermes, which provides technology to make long lasting drugs.
Copyright 2007-2009
Read on »
1 Comment
